Search

Endostatin

INCB-057643

INCB-057643 is under investigation in clinical trial NCT02959437 (Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)).

ZD4407

It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

Tradipitant

[A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. … [L54903] Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.[A275348, A275358, A275363]

Teplizumab

[L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and lead to severe adverse effects related to cytokine release syndrome (CRS). … Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS.

Colfosceril palmitate

Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. … [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.

ME-344

ME-344 has been used in trials studying the treatment of Solid Tumors.

MGD-024

MGD-024 is an anti-CD123/anti-CD3 bispecific DART molecule.

Equine Botulinum Neurotoxin B Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients.

Nomegestrol acetate

Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.